Re: Conclusion: Newer Anticoagulants

[Guest guest]

CongratsThat was a candid & brief presentation by Dr. Vijay ThawaniI would to like to offer one suggestion for the future presenters in the forum.After starting a topic one can continue in the same page - for this one has to click the reply button and post the second or subsequent contents of the same topic.the advantage lies in archiving - one can save after the final post (which will contain all the info of that topic posted by the author).as of now one has to select each and every mail and put it in a folder;further in case one wants to revisit the topic one has to again open each and

every mail.thanks for allowing me to post this suggestionG. SivagnanamFrom: Vijaya Chaudhari <vijugmc@...>netrum Sent: Thu, January 13, 2011 6:16:47 PMSubject: Conclusion: Newer Anticoagulants

Dear Members, First of all I am extremely thankful to Dr. Vijay Thawani Sir for giving me an opportunity to

moderate this E-discussion on 'Newer anticoagulants' on the NetRUM. To conclude, although the newer anticoagulants specially the oral ones (Ximelagatran, Dabigatran, Rivaroxaban, Apixaban) are recently introduced and under/ just cleared phase III clinical trials; due to their favorable efficacy & safety profiles, it appears that these medicines are poised to challenge warfarin's dominance in the prevention and therapy of thrombotic disease. Regards,Dr. Vijaya Chaudhari.JR-3,Dept. of Pharmacology,Government Medical College, Nagpur.

[Guest guest]

Hi Sivagnanam,

The compliments must go to Dr Vijaya Chaudhari and not me!

Vijaya: these were meant for you. Even from me!

Vijay

>

> Congrats

> That was a candid & brief presentation by Dr. Vijay Thawani

>

> I would to like to offer one suggestion for the future presenters in the

forum.

> After starting a topic one can continue in the same page -

> for this one has to click the reply button and post the second or subsequent

> contents of the same topic.

> the advantage lies in archiving - one can save after the final post (which

will

> contain all the info of that topic posted by the author).

> as of now one has to select each and every mail and put it in a folder;

> further in case one wants to revisit the topic one has to again open each and

> every mail.

> thanks for allowing me to post this suggestion

>

> G. Sivagnanam

>

>

>

>

>

>

> ________________________________

> From: Vijaya Chaudhari <vijugmc@...>

> netrum

> Sent: Thu, January 13, 2011 6:16:47 PM

> Subject: Conclusion: Newer Anticoagulants

>

>

> Dear Members,

>

> First of all I am extremely thankful to Dr. Vijay Thawani Sir for giving me an

> opportunity to moderate this E-discussion on 'Newer anticoagulants' on the

> NetRUM.

>

> To conclude, although the newer anticoagulants specially the oral ones

> (Ximelagatran, Dabigatran, Rivaroxaban, Apixaban) are recently introduced and

> under/ just cleared phase III clinical trials; due to their favorable efficacy

&

> safety profiles, it appears that these medicines are poised to challenge

> warfarin's dominance in the prevention and therapy of thrombotic disease.

> Regards,

> Dr. Vijaya Chaudhari.

> JR-3,Dept. of Pharmacology,

> Government Medical College, Nagpur.

>